Amalgamated Financial’s Cytokinetics CYTK Stock Holding History

Amalgamated Financial’s Portfolio CYTK Stock Details CYTK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	$1.47M	Buy	+39,919	New	+$1.42M	0.01%	1021

Other funds holding CYTK

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

PAMS

Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

Amalgamated Financial's CYTK Position: Q1 2022 in Review

Amalgamated Financial opened a new position in Cytokinetics (CYTK) in Q1 2022: 39,919 shares worth $1.47M. The stake represents 0.01% of the portfolio and ranks #1021 among its holdings.

240 funds tracked by Wall St. Rank hold CYTK as of Q1 2022.

Amalgamated Financial held 39,919 shares of Cytokinetics worth $1.47M as of Q1 2022.
Cytokinetics was a new Amalgamated Financial position in Q1 2022.
Cytokinetics made up 0.01% of Amalgamated Financial's portfolio in Q1 2022, its #1021 holding.
240 funds tracked by Wall St. Rank held Cytokinetics as of Q1 2022.

Based on Amalgamated Financial's 13F filing for Q1 2022, filed 16 May 2022.